1 option
Pharmacoeconomic review report Adalimumab (Humira) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Cost effectiveness.
- Physical Description:
- 1 online resource (viii, 39 pages)
- Other Title:
- Pharmacoeconomic review report Adalimumab
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2016.
- Summary:
- Adalimumab (Humira) is an anti-℗tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6-Amercaptopurine (6-℗MP), or who are intolerant to such therapies.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.